Nature Editorial: FDA Needs Help Assessing Cutting-Edge Tech
Published 07 August 2017
The US Food and Drug Administration (FDA) is increasingly being tasked with evaluating cutting-edge therapies and technology that its in-house expertise may not be able to address, according to a Nature editorial, which recommends academic scientists help the agency.
Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs, Regulatory intelligence, Regulatory strategy
Tags: CAR-T, academic scientists, Scott Gottlieb